Back to Results
First PageMeta Content
Histopathology / End point of clinical trials / Response Evaluation Criteria in Solid Tumors / Vismodegib / Medicine / Basal-cell carcinoma / Carcinoma


Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6
Add to Reading List

Document Date: 2014-05-12 19:51:02

Open Document

File Size: 321,96 KB

Share Result on Facebook

City

Denver / South San Francisco / Orlando / Antwerp / Houston / Nashville / Essen / /

Company

F. Hoffmann-La Roche Ltd. / Chugai Pharmaceuticals / Curis Inc. / Eastern Cooperative Oncology Group / 10Genentech Inc. / Genentech / /

Country

Germany / Belgium / Japan / United States / Korea / /

Event

Business Partnership / Product Issues / Product Recall / /

Facility

Colorado Cancer Center / Cannon Research Institute / 11University Hospital / Augustinus Hospital / Texas MD Anderson Cancer Center / University School / /

MedicalCondition

bRadiographically measurable disease / tumor / Basal cell carcinoma / measurable disease / disease / nodal metastases / Solid Tumors / Progressive disease / recurrences Significant morbidity/deformity / advanced basal cell carcinoma / deformity / Stable disease / /

MedicalTreatment

radiation therapy / radiotherapy / surgery / /

Organization

3Stanford University School of Medicine / Colorado Cancer Center / 4Sint-Augustinus Hospital / US Food and Drug Administration / 6Sarah Cannon Research Institute / FDA / 11University Hospital Essen / Stanford / /

Person

Hou / /

Position

investigator / driver / LoRusso PM / independent pathologist / Physician / /

Product

study / /

ProvinceOrState

Texas / Nebraska / Illinois / /

Region

Central Florida / /

Technology

radiation / /

SocialTag